Cephalon Likely To Launch In-House Actiq Generic To Compete With Barr

Cephalon is planning to launch an in-house generic version of Actiq (transmucosal fentanyl) to compete with Barr, the company said

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet